Le cancer de la prostate neuro-endocrine : histoire naturelle, caractéristiques moléculaires, prise en charge et perspectives [Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions]

Details

Serval ID
serval:BIB_648992D13384
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Le cancer de la prostate neuro-endocrine : histoire naturelle, caractéristiques moléculaires, prise en charge et perspectives [Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions]
Journal
Bulletin du cancer
Author(s)
Campedel L., Kossaï M., Blanc-Durand P., Rouprêt M., Seisen T., Compérat E., Spano J.P., Malouf G.
ISSN
1769-6917 (Electronic)
ISSN-L
0007-4551
Publication state
Published
Issued date
09/2017
Peer-reviewed
Oui
Volume
104
Number
9
Pages
789-799
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Neuroendocrine prostate cancer is a rare malignancy with a an adverse prognostic. Histologically, It can be pure (small cells or large cells neuroendocrine carcinoma) or mixed with a adenocarcinoma component. Rarely diagnosed de novo, neuroendocrine prostate cancer is generally associated with advanced stage disease resistant to castration. As such, this histological subtype could represent an aggressive evolution of prostatic adenocarcinoma, through the epithelio-neuroendocrine transdifferentiation mechanism (phenomenon of lineage plasticity). Nonetheless, neuroendocrine prostate cancer is a heterogeneous malignancy with multiple histopathological variants showing distinct clinical features. The broad variety of molecular analyses could help to understand the ontogeny of this histological subtype and its signaling pathways. This may also allow identifying diagnostic and prognostic biomarkers as well as potential molecular targets. However, treatment options are currently limited and consist only in platinium-based chemotherapy for advanced stage disease.

Keywords
Adenocarcinoma/pathology, Antineoplastic Agents/therapeutic use, Carcinoma, Neuroendocrine/diagnostic imaging, Carcinoma, Neuroendocrine/drug therapy, Carcinoma, Neuroendocrine/genetics, Carcinoma, Neuroendocrine/pathology, Humans, Immunohistochemistry, Male, Phenotype, Platinum Compounds/therapeutic use, Prostatic Neoplasms/diagnostic imaging, Prostatic Neoplasms/drug therapy, Prostatic Neoplasms/genetics, Prostatic Neoplasms/pathology, Rare Diseases/diagnostic imaging, Rare Diseases/drug therapy, Rare Diseases/genetics, Rare Diseases/pathology, Cancer de la prostate neuro-endocrine, Cancer de la prostate résistant à la castration, Castration-resistant prostate cancer, Neuroendocrine prostate cancer, Neuroendocrine transdifferentiation, Plasticité tissulaire, Tissular plasticity, Transdifférenciation neuro-endocrine
Pubmed
Web of science
Create date
27/07/2017 13:08
Last modification date
20/08/2019 14:20
Usage data